AXGN AxoGen, Inc. Stock Quote

AXGN [NASD]

Index	-	P/E	-	EPS (ttm)	-0.68	Insider Own	4.10%	Shs Outstand	41.47M	Perf Week	-5.43%
Market Cap	398.18M	Forward P/E	-	EPS next Y	-0.36	Insider Trans	-2.51%	Shs Float	39.70M	Perf Month	-39.00%
Income	-27.70M	PEG	-	EPS next Q	-0.07	Inst Own	79.80%	Short Float	1.26%	Perf Quarter	-43.99%
Sales	128.30M	P/S	3.10	EPS this Y	19.90%	Inst Trans	-1.67%	Short Ratio	2.51	Perf Half Y	-53.29%
Book/sh	2.78	P/B	3.32	EPS next Y	38.10%	ROA	-13.50%	Target Price	25.17	Perf Year	-35.81%
Cash/sh	2.13	P/C	4.34	EPS next 5Y	-	ROE	-23.20%	52W Range	9.11 - 23.94	Perf YTD	-48.44%
Dividend	-	P/FCF	-	EPS past 5Y	-3.00%	ROI	-14.90%	52W High	-61.01%	Beta	0.70
Dividend %	-	Quick Ratio	5.10	Sales past 5Y	32.70%	Gross Margin	80.00%	52W Low	2.47%	ATR	0.77
Employees	346	Current Ratio	5.80	Sales Q/Q	-6.60%	Oper. Margin	-19.80%	RSI (14)	26.30	Volatility	7.37% 6.58%
Optionable	Yes	Debt/Eq	0.40	EPS Q/Q	-366.80%	Profit Margin	-21.60%	Rel Volume	1.96	Prev Close	9.23
Shortable	Yes	LT Debt/Eq	0.40	Earnings	Nov 03 AMC	Payout	-	Avg Volume	199.02K	Price	9.34
Recom	1.90	SMA20	-23.09%	SMA50	-32.70%	SMA200	-48.55%	Volume	182,120	Change	1.14%

Oct-23-20

Initiated

Guggenheim

Buy

$24

Jun-16-20

Resumed

Cantor Fitzgerald

Overweight

$16

May-07-20

Downgrade

Canaccord Genuity

Buy → Hold

$12

Apr-02-20

Downgrade

BTIG Research

Buy → Neutral

Aug-07-19

Downgrade

William Blair

Outperform → Mkt Perform

Jul-12-19

Initiated

Canaccord Genuity

Buy

$32

Mar-02-18

Reiterated

Lake Street

Buy

$26 → $38

Jan-05-18

Resumed

Cantor Fitzgerald

Overweight

Nov-30-17

Initiated

Jefferies

Buy

$35

Nov-21-17

Reiterated

Lake Street

Buy

$22 → $26

Jul-31-17

Initiated

Leerink Partners

Outperform

$22

Jun-30-17

Initiated

Cantor Fitzgerald

Overweight

$18

Mar-06-17

Initiated

ROTH Capital

Buy

$14.50

Nov-22-16

Upgrade

Lake Street

Hold → Buy

$9 → $11

Nov-07-16

Reiterated

Wedbush

Outperform

$10 → $12

Nov-03-16

Downgrade

Lake Street

Buy → Hold

Aug-04-16

Reiterated

Wedbush

Outperform

$9 → $10

May-14-14

Initiated

Dawson James

Buy

Oct-31-13

Reiterated

Ladenburg Thalmann

Buy

$4.50 → $5.75

Nov-10-21 07:00AM	Axogen, Inc. to Participate at Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum GlobeNewswire
Nov-04-21 07:00AM	Axogen, Inc. to Participate at Jefferies London Healthcare Conference GlobeNewswire -15.26%
Nov-03-21 09:31PM	AxoGen, inc (AXGN) Q3 2021 Earnings Call Transcript Motley Fool
05:15PM	AxoGen (AXGN) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:01PM	Axogen, Inc. Reports 2021 Third Quarter Financial Results GlobeNewswire
Oct-27-21 03:03PM	AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Oct-17-21 08:40AM	AxoGen (NASDAQ:AXGN) investors are sitting on a loss of 59% if they invested three years ago Simply Wall St.
Oct-13-21 07:00AM	Axogen, Inc. to Report Third Quarter Financial Results and Host Conference Call on November 3, 2021 GlobeNewswire
Sep-22-21 07:00AM	Axogen to Participate in the 76th Annual Meeting of the American Society for Surgery of the Hand GlobeNewswire
Sep-01-21 07:00AM	Axogen RECON(SM) Clinical Study Completes Subject Follow-up GlobeNewswire
Aug-18-21 06:35AM	Could The AxoGen, Inc. (NASDAQ:AXGN) Ownership Structure Tell Us Something Useful? Simply Wall St.
Aug-05-21 04:30AM	AxoGen, inc (AXGN) Q2 2021 Earnings Call Transcript Motley Fool
Aug-04-21 05:55PM	AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:01PM	Axogen, Inc. Reports 2021 Second Quarter Financial Results GlobeNewswire
Jul-28-21 03:03PM	AxoGen (AXGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Jul-22-21 07:00AM	Axogen, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference GlobeNewswire
Jul-19-21 04:01PM	Axogen, Inc. Appoints John H. Johnson to Board of Directors GlobeNewswire
Jul-14-21 07:00AM	Axogen, Inc. to Report Second Quarter Financial Results and Host Conference Call on August 4, 2021 GlobeNewswire
Jun-19-21 03:24AM	Health Check: How Prudently Does AxoGen (NASDAQ:AXGN) Use Debt? Simply Wall St.
May-18-21 08:43AM	Axogen To Stop Commercial Sales Of Avive Soft Tissue Membrane Pending Discussions With FDA Benzinga
07:00AM	Axogen, Inc. to present at the Jefferies Virtual Healthcare Conference and the JMP Securities Life Sciences Conference GlobeNewswire
May-07-21 08:56AM	AxoGen (AXGN) Stock Jumps 12.5%: Will It Continue to Soar? Zacks +6.38%
May-06-21 07:00AM	Axogen, Inc. to Present at the Canaccord Genuity Musculoskeletal Conference GlobeNewswire +12.47%
12:31AM	AxoGen Inc (AXGN) Q1 2021 Earnings Call Transcript Motley Fool
May-05-21 05:15PM	AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:00PM	Axogen, Inc. Reports 2021 First Quarter Financial Results GlobeNewswire
02:45PM	AxoGen, Inc. to Host Earnings Call ACCESSWIRE
Apr-28-21 12:34PM	AxoGen (AXGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Apr-20-21 02:06AM	If You Had Bought AxoGen (NASDAQ:AXGN) Stock Five Years Ago, You Could Pocket A 224% Gain Today Simply Wall St.
Apr-14-21 07:00AM	Axogen, Inc. to Report First Quarter Financial Results and Host Conference Call on May 5, 2021 GlobeNewswire
Mar-01-21 04:01PM	Axogen, Inc. Promotes Peter J. Mariani to Executive Vice President and Chief Financial Officer GlobeNewswire
Feb-22-21 04:01PM	Axogen, Inc. Reports 2020 Fourth Quarter and Full-Year Financial Results GlobeNewswire
02:30PM	AxoGen, Inc. to Host Earnings Call ACCESSWIRE
Feb-19-21 10:16AM	A Preview Of Axogen's Earnings Benzinga
Feb-18-21 11:47PM	AxoGen, Inc. (NASDAQ:AXGN): Is Breakeven Near? Simply Wall St.
07:00AM	Axogen Sponsored REPOSE Study Completes Pilot Phase Analysis GlobeNewswire
Feb-04-21 07:00AM	Axogen, Inc. to Participate at Upcoming February Investor Conferences GlobeNewswire
Feb-01-21 07:00AM	Axogen, Inc. to Report Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call on February 22, 2021 GlobeNewswire
Jan-11-21 07:00AM	Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2020 GlobeNewswire
Jan-05-21 07:00AM	Axogen to Participate at AAHS ASPN ASRM 2021 Virtual Annual Meetings GlobeNewswire
Jan-04-21 11:22PM	Do Institutions Own AxoGen, Inc. (NASDAQ:AXGN) Shares? Simply Wall St.
Dec-23-20 07:00AM	Axogen Sponsors Donate Life at 2021 Virtual Rose Parade Celebration GlobeNewswire
Dec-15-20 10:17PM	Is AXGN A Good Stock To Buy Now? Insider Monkey
Nov-06-20 05:38AM	Is AxoGen (NASDAQ:AXGN) A Risky Investment? Simply Wall St.
Nov-04-20 07:00AM	Axogen, Inc. to Participate at Jefferies Virtual London Healthcare Conference and Canaccord Genuity Virtual MedTech & Diagnostics Forum GlobeNewswire
Oct-30-20 02:31PM	AxoGen Inc (AXGN) Q3 2020 Earnings Call Transcript Motley Fool
Oct-29-20 06:55PM	AxoGen (AXGN) Beats Q3 Earnings and Revenue Estimates Zacks
04:01PM	Axogen, Inc. Reports Third Quarter 2020 Financial Results GlobeNewswire
02:45PM	AxoGen, Inc.to Host Earnings Call ACCESSWIRE
Oct-28-20 10:15AM	Earnings Outlook For Axogen Benzinga
Oct-08-20 07:00AM	Axogen, Inc. to Report Third Quarter 2020 Financial Results and Host Conference Call on October 29, 2020 GlobeNewswire
Sep-30-20 04:01PM	Axogen, Inc. Appoints Paul G. Thomas to Board of Directors GlobeNewswire
Sep-25-20 07:00AM	Axogen, Inc. to Present at the JMP Securities MedTech Bio Summit GlobeNewswire
Sep-24-20 07:00AM	Axogen to Participate in the 75th Annual American Society for Surgery of the Hand Meeting GlobeNewswire
Aug-31-20 07:00AM	Axogen, Inc. to Present at the Cantor Virtual Global Healthcare Conference GlobeNewswire
Aug-07-20 09:48AM	Is AxoGen's (NASDAQ:AXGN) 219% Share Price Increase Well Justified? Simply Wall St.
Aug-05-20 07:45PM	AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:01PM	Axogen, Inc. Reports Second Quarter 2020 Financial Results GlobeNewswire
Jul-29-20 12:33PM	Earnings Preview: AxoGen (AXGN) Q2 Earnings Expected to Decline Zacks
07:00AM	Axogen, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference GlobeNewswire
Jul-22-20 07:00AM	Axogen RECON Clinical Study Completes Target Enrollment of 220 Subjects GlobeNewswire
Jul-15-20 07:00AM	Axogen, Inc. to Report Second Quarter 2020 Financial Results and Host Conference Call on August 5, 2020 GlobeNewswire +6.12%
Jul-08-20 06:41PM	Is AxoGen, Inc. (AXGN) Going to Burn These Hedge Funds? Insider Monkey
Jul-01-20 07:00AM	Axogen Announces New Seven-Year Financing Agreement with Oberland Capital and Provides Preliminary Second Quarter Revenue Estimate GlobeNewswire +26.95%
Jun-23-20 09:46AM	Edited Transcript of AXGN.OQ earnings conference call or presentation 6-May-20 8:30pm GMT Thomson Reuters StreetEvents +6.38%
Jun-01-20 07:00AM	Axogen, Inc. Announces Planned Retirement of Greg Freitag and Appoints Brad Ottinger as General Counsel and Chief Compliance Officer GlobeNewswire
May-20-20 07:00AM	Axogen, Inc. to Present at the Jefferies Virtual Healthcare Conference GlobeNewswire
May-07-20 12:00PM	AxoGen Inc (AXGN) Q1 2020 Earnings Call Transcript Motley Fool -15.87%
May-06-20 04:01PM	Axogen, Inc. Reports First Quarter 2020 Financial Results GlobeNewswire
Apr-29-20 12:34PM	Earnings Preview: AxoGen (AXGN) Q1 Earnings Expected to Decline Zacks +11.45%
Apr-23-20 07:00AM	Axogen, Inc. Reports Preliminary Revenue for the First Quarter 2020, Provides Business Update in Response to COVID-19 Pandemic, and Announces Dismissal of Class Action Lawsuit GlobeNewswire
Apr-15-20 07:00AM	Axogen, Inc. to Report First Quarter 2020 Financial Results and Host Conference Call on May 6, 2020 GlobeNewswire -6.23%
Apr-12-20 09:21AM	Is AxoGen, Inc.'s (NASDAQ:AXGN) CEO Being Overpaid? Simply Wall St.
Mar-06-20 07:05AM	Edited Transcript of AXGN earnings conference call or presentation 24-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Mar-02-20 07:00AM	Axogen, Inc. to Participate at Upcoming Investor Conferences GlobeNewswire
Feb-27-20 07:20AM	AxoGen, Inc. Just Reported, And Analysts Assigned A US$22.17 Price Target Simply Wall St.
Feb-24-20 04:01PM	Axogen, Inc. Reports Fourth Quarter and Full-Year 2019 Financial Results GlobeNewswire
Feb-23-20 06:38PM	The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace Benzinga
Feb-05-20 07:00AM	Axogen, Inc. to Present at the Leerink Partners 9th Annual Global Healthcare Conference GlobeNewswire
Feb-03-20 07:00AM	Axogen, Inc. to Report Fourth Quarter and Full-Year 2019 Financial Results and Host Conference Call on February 24, 2020 GlobeNewswire
05:55AM	How Many AxoGen, Inc. (NASDAQ:AXGN) Shares Did Insiders Buy, In The Last Year? Simply Wall St.
Jan-13-20 07:00AM	Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2019 and Provides 2020 Annual Guidance GlobeNewswire -11.07%
Jan-08-20 07:00AM	Axogen Sponsored RANGER® Registry Reaches 2,000 Nerve Repair Enrollment Milestone GlobeNewswire
Jan-02-20 04:01PM	Axogen to Participate at AAHS ASPN ASRM 2020 Annual Meetings GlobeNewswire
07:00AM	Axogen, Inc. to Participate at JP Morgan 38th Annual Healthcare Conference GlobeNewswire
Dec-19-19 06:47AM	Can You Imagine How Elated AxoGen's (NASDAQ:AXGN) Shareholders Feel About Its 335% Share Price Gain? Simply Wall St.
Dec-18-19 07:00AM	Axogen awarded research grant from the Advanced Regenerative Manufacturing Institute GlobeNewswire
Dec-13-19 11:03AM	Hedge Funds Cashed Out Of AxoGen, Inc. (AXGN) Too Early Insider Monkey
Dec-04-19 07:00AM	Avance® Nerve Graft Recipient Selected to Ride on Donate Life Rose Parade® Float GlobeNewswire
Nov-22-19 12:19PM	Edited Transcript of AXGN earnings conference call or presentation 6-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-21-19 07:00AM	Axogen, Inc. to Participate at Piper Jaffray 31st Annual Healthcare Conference GlobeNewswire
Nov-11-19 07:00AM	Axogen, Inc. to Participate at Jefferies London Healthcare Conference GlobeNewswire
Nov-09-19 07:02PM	Hedge Funds Arent Crazy About AxoGen, Inc. (AXGN) Anymore Insider Monkey
Nov-06-19 06:35PM	AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:04PM	Axogen, Inc. Reports 2019 Third Quarter Financial Results GlobeNewswire
Nov-04-19 06:12AM	Here's Why We're Not Too Worried About AxoGen's (NASDAQ:AXGN) Cash Burn Situation Simply Wall St.
Oct-30-19 10:34AM	Earnings Preview: AxoGen (AXGN) Q3 Earnings Expected to Decline Zacks
Oct-23-19 07:00AM	Axogen, Inc. to Report Third Quarter 2019 Financial Results and Host Conference Call on November 6, 2019 GlobeNewswire
Oct-03-19 01:40PM	Scott+Scott Attorneys at Law LLP Investigating Axogen, Inc.'s Directors and Officers for Breach of Fiduciary Duties - AXGN PR Newswire
Sep-20-19 10:38AM	Why AxoGen, Inc.'s (NASDAQ:AXGN) CEO Pay Matters To You Simply Wall St.

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zaderej Karen L.	CEO	Nov 24	Option Exercise	8.95	52,375	468,756	921,147	Nov 29 04:09 PM
Zaderej Karen L.	CEO	Aug 13	Option Exercise	3.67	46,500	170,655	868,772	Aug 16 04:10 PM
Zaderej Karen L.	CEO	Aug 12	Option Exercise	5.09	8,254	42,013	822,272	Aug 16 04:10 PM
Zaderej Karen L.	CEO	Aug 10	Option Exercise	5.09	75,000	381,750	855,018	Aug 10 04:52 PM
Zaderej Karen L.	CEO	Aug 06	Sale	18.47	41,000	757,194	814,018	Aug 10 04:52 PM
Donovan Michael Patrick	VP Operations	Jul 21	Sale	20.04	1,935	38,777	40,839	Jul 23 04:06 PM
Freitag Gregory Gene	Director	Jun 17	Option Exercise	19.17	9,250	177,323	364,556	Jun 21 04:17 PM
MARTINEZ MARIA D.	Chief Human Resources Officer	Jun 04	Sale	18.86	2,652	50,017	2,932	Jun 08 04:25 PM
Gold Mark Stephen	Director	Jun 01	Option Exercise	0.00	6,173	0	302,439	Jun 03 05:15 PM
Wendell Amy McBride	Director	Jun 01	Option Exercise	0.00	6,173	0	32,097	Jun 03 05:14 PM
NEELS GUIDO J	Director	Jun 01	Option Exercise	0.00	6,173	0	48,764	Jun 03 05:12 PM
Blackford Quentin S.	Director	Jun 01	Option Exercise	0.00	6,173	0	24,299	Jun 03 05:13 PM
Levine Alan M	Director	Jun 01	Option Exercise	0.00	6,173	0	8,764	Jun 03 05:11 PM
Freitag Gregory Gene	Director	May 26	Option Exercise	6.72	102,954	692,001	331,306	May 28 04:05 PM
NEELS GUIDO J	Director	May 19	Option Exercise	4.28	40,000	171,350	42,591	May 21 04:21 PM
DeVinney Erick Wayne	VP of Clin. & Trans. Sciences	Apr 28	Option Exercise	2.86	10,000	28,600	78,082	Apr 30 04:10 PM
Zaderej Karen L.	CEO	Apr 16	Option Exercise	5.09	100,000	509,000	765,912	Apr 20 04:09 PM
Zaderej Karen L.	CEO	Mar 25	Option Exercise	3.67	34,500	126,615	665,912	Mar 29 04:17 PM
Freitag Gregory Gene	Director	Feb 25	Sale	22.06	24,000	529,440	228,352	Mar 01 04:08 PM
Donovan Michael Patrick	VP Operations	Feb 18	Sale	19.15	1,808	34,623	40,839	Feb 19 04:12 PM
Donovan Michael Patrick	VP Operations	Feb 05	Option Exercise	5.14	20,000	102,800	46,029	Feb 09 07:12 PM
Zaderej Karen L.	CEO	Jan 08	Sale	20.00	65,000	1,300,000	609,099	Jan 12 04:08 PM
Donovan Michael Patrick	VP Operations	Dec 30	Sale	17.48	1,733	30,293	26,029	Dec 31 04:06 PM
DeVinney Erick Wayne	VP, Clinical&Translational Sc	Dec 29	Sale	17.81	371	6,608	63,240	Dec 30 05:33 PM
Donovan Michael Patrick	VP Operations	Dec 29	Sale	17.81	567	10,098	27,762	Dec 30 04:09 PM
Freitag Gregory Gene	Director	Dec 29	Sale	17.81	916	16,314	248,345	Dec 30 12:53 PM
Scopelianos Angelo	VP Research & Development	Dec 29	Sale	17.81	567	10,098	5,529	Dec 30 11:55 AM
MARIANI PETER J	Chief Financial Officer	Dec 29	Sale	17.81	1,293	23,028	10,376	Dec 30 11:56 AM
Zaderej Karen L.	CEO	Dec 29	Sale	17.81	3,500	62,335	674,099	Dec 30 11:53 AM
MARTINEZ MARIA D.	Chief Human Resources Officer	Dec 29	Sale	17.81	567	10,098	4,665	Dec 30 11:51 AM
Friedman Mark Louis	VP,Regulatory & Quality	Dec 29	Sale	17.81	567	10,098	11,124	Dec 30 11:52 AM
Billet Isabelle	Chief Strategy and BD Officer	Dec 29	Sale	17.81	649	11,559	9,496	Dec 30 11:51 AM
Zaderej Karen L.	CEO	Dec 23	Option Exercise	4.81	19,375	93,194	666,094	Dec 28 09:26 AM
Donovan Michael Patrick	VP Operations	Dec 22	Sale	17.19	279	4,796	26,029	Dec 23 02:32 PM
Zaderej Karen L.	CEO	Dec 21	Sale	16.42	1,275	20,936	646,719	Dec 22 05:32 PM
Friedman Mark Louis	VP,Regulatory & Quality	Dec 21	Sale	16.42	96	1,576	8,893	Dec 22 11:38 AM
DeVinney Erick Wayne	VP, Clinical&Translational Sc	Dec 21	Sale	16.42	147	2,414	62,111	Dec 22 03:22 PM
Freitag Gregory Gene	Director	Dec 21	Sale	16.42	379	6,223	245,076	Dec 22 03:15 PM
Donovan Michael Patrick	VP Operations	Dec 21	Sale	16.42	96	1,576	26,308	Dec 22 01:55 PM
MARIANI PETER J	Chief Financial Officer	Dec 21	Sale	16.42	481	7,898	6,419	Dec 22 12:54 PM
DeVinney Erick Wayne	VP, Clinical&Translational Sc	Dec 15	Option Exercise	4.81	15,000	72,150	66,056	Dec 17 04:41 PM
Friedman Mark Louis	VP,Regulatory & Quality	Dec 03	Option Exercise	3.86	3,812	14,703	8,614	Dec 07 02:39 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience